RT Journal Article
SR Electronic
T1 Preventing antimalarial drug resistance with triple artemisinin-based combination therapies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.21.22281347
DO 10.1101/2022.10.21.22281347
A1 Nguyen, Tran Dang
A1 Gao, Bo
A1 Amaratunga, Chanaki
A1 Dhorda, Mehul
A1 Tran, Thu Nguyen-Anh
A1 White, Nicholas J
A1 Dondorp, Arjen M
A1 Boni, Maciej F
A1 Aguas, Ricardo
YR 2022
UL http://medrxiv.org/content/early/2022/10/22/2022.10.21.22281347.abstract
AB Background Increasing levels of artemisinin and partner drug resistance threaten malaria control and elimination globally. Triple artemisinin-based combination therapies (TACTs) which combine artemisinin derivatives with two partner drugs are efficacious and well tolerated in clinical trials, including in areas of multidrug-resistant malaria. Whether early TACT adoption could delay the emergence and spread of antimalarial drug resistance is a question of vital importance.Methods Using two independent individual-based models of Plasmodium falciparum epidemiology and evolution, we evaluated whether introduction of either artesunate-mefloquine-piperaquine or artemether-lumefantrine-amodiaquine resulted in lower long-term artemisinin-resistance levels and treatment failure rates compared with continued ACT use.Findings In countries with 1% P. falciparum prevalence, immediate adoption of TACTs would result in substantially lower frequency of artemisinin-resistant alleles 10 years later. Median estimates were 70%, 33%, and 18% lower allele frequency for countries currently deploying dihydroartemisinin-piperaquine, artesunate-amodiaquine, or artemether-lumefantrine, respectively. Corresponding median treatment failure rate decreases are 74%, 34%, and 17%. Delaying TACT introduction increases future resistance frequencies and treatment failure rates. The most significant threat to the success of TACTs is the emergence of a triple-resistant genotype. which if above 0.01 frequency may undermine elimination efforts in low-prevalence regions.Interpretation Introduction of TACTs could delay the emergence and spread of artemisinin resistance and treatment failure, extending the useful therapeutic life of current antimalarial drugs and improving the chances of malaria elimination. Immediate introduction of TACTs should be considered by policy makers in areas of emerging artemisinin resistance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research falls under the auspices of the Development of Triple Artemisinin-based Combination Therapies (DeTACT) project funded by UK Aid and the UK Government Foreign, Commonwealth and Development Office. Funding from Wellcome Trust (220211) is also acknowledged. MFB, TDN, TN-AT acknowledge funding from the National Institutes of Health grant NIAID R01AI153355 and The Bill and Melinda Gates Foundation INV-005517 grant awarded to Pennsylvania State University. RA acknowledges funding from the Bill and Melinda Gates Foundation (OPP1193472). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://github.com/ATOME-MORU/deTACT https://github.com/ATOME-MORU/deTACT